The purpose of this study is to evaluate the efficacy of sorafenib in patients with
Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at
400mg orally twice a day, given on days 1-28 of a 28-day cycle. Patients will be evaluated
for hematological response after 2 cycles and then every 3 cycles thereafter for a maximum of
5 years from study entry. If a patient achieves a complete response they may receive an
additional 6 cycles of therapy beyond documentation of complete response unless unacceptable
toxicity occurs. For patients with partial response, hematological improvement or stable
disease they will continue treatment until relapse, progression of disease, or unacceptable
toxicity occurs.